CTIS2024-514348-95-00进行中（未招募）1 期
APISApixaban for Intrahepatic Non Cirrhotic Portal Hypertension - P170916J
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 166
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •>/=18 and = 90 year old male and female patients, - For child-bearing aged women, contraception using progestatives, or intrauterine device or mechanical contraception, - Adequate prophylaxis against variceal bleeding according to EASL (European association for the study of the liver) guidelines, - Intrahepatic non cirrhotic portal hypertension (INCPH), defined according to the recent VALDIG workshop (Feb. 2017, Ascona, Italy) as having one of the following simultaneous associations: a.absence of cirrhosis on an adequate liver biopsy, and one or more signs specific for portal hypertension b.absence of cirrhosis on an adequate liver biopsy, and one or more signs not specific for portal hypertension and one or more histological signs for INCPH c.in the absence of adequate liver biopsy, 2 reliable liver stiffness values determined using transient elastography (Fibroscan) < 10 kPa and one or more signs specific for portal hypertension
排除标准
- •oMyeloproliferative disease treated with aspirin to prevent vascular events, paroxysmal nocturnal hemoglobinuria., oActive clinically significant bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities., oPlatelet < 40000/mm3, or prothrombin index <40% in the absence of anti-vitamin K or Factor V < 40% or Fibrinogen < 1.0g/L, oTransjugular intrahepatic portosystemic shunt (TIPSS) or surgical portosystemic shunt, oParticipation in another interventional trial, oCreatinine clearance < 30 mL/min, oHepatitis C with detectable HCV RNA at inclusion, oPositive HBs Ag, except patients with HBeAg-negative chronic HBV infection, previously termed ‘inactive carriers’ [characterised by the presence of serum antibodies to HBeAg (anti-HBe), undetectable or low (<2,000 IU/mL) HBV DNA levels and normal serum ALT levels] that can be included, oAlcohol intake >210 g/week for men and 140 g/week for women, oMandatory indicationb to aspirin or other antiplatelet agents including P2Y12 receptor antagonists, oPatient who underwent liver transplantation less than 3 years before screening, oOngoing oestroprogestative contraception, oSevere hepatic impairment or significant active liver injury (serum ALT level > 5 times the upper limit of normal values), oLife expectancy <12 months, oSpecific causes of portal hypertension or specific vascular liver diseases: history of bone marrow transplantation, Budd-Chiari syndrome / hepatic venous outflow obstruction, hepatic schistosomiasis diagnosed on liver biopsy (an isolated positive serology is not an exclusion criterion), cardiac failure, Fontan surgery, Abernethy syndrome, Hereditary hemorrhagic telangiectasia, chronic cholestatic diseases, liver infiltration by tumor cells, oConcomitant use of potent inhibitors of CYP3A4 or P-gp. In case of moderate interactions with apixaban (for example, immunosuppressive treatment), the dose of CYP3A4 inhibitor will be adapted according to its plasmatic level in the study patient., oHypersensitivity to the active substance or to any of the excipients including lactose., oPatients unable to give consent (under guardianship or curatorship), oNo written informed consent for participation in the study, oNo coverage for medical insurance, oPregnant or breastfeeding women, oComplete thrombosis of superior mesenteric vein and/or inferior mesenteric vein, oComplete portal vein thrombosis or portal cavernoma, oRecent (<6 months) partial portal venous system thrombosis, oMandatory indicationa or contraindication to anticoagulation, oConcomitant treatment with any other anticoagulant agent unless when bridging from one to the other is performed, oDisease at high risk of bleeding (except for portal hypertension)
研究者
相似试验
进行中（未招募）
3 期
Apixaban for Intrahepatic Non Cirrhotic Portal HypertensionIntrahepatic Non Cirrhotic Portal HypertensionNCT04007289Assistance Publique - Hôpitaux de Paris166
招募中
不适用
Idiopathic non-cirrhotic intrahepatic portal hypertension (INCIPH): assessment of thrombophilia and histopathology in a multicentre cohort study and HIV patients.NL-OMON35427Erasmus MC, Universitair Medisch Centrum Rotterdam50
进行中（未招募）
不适用
Intra-Arterial hepatic administration of SIR-Spheres for the advanced HEPATOCARCINOMA. CLINICAL TRIAL OF PHASE II - NDEUCTR2005-005183-82-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI20
已完成
不适用
A Novel Approach for Transjugular Intrahepatic Portocaval Shunt Creation Using Real-time Three Dimensional RoadmapPortal HypertensionNCT03031366West China Hospital30
已完成
不适用
Covered transjugular intrahepatic portosystemic stent shunt versus optimised medical treatment for the secondary prevention of variceal bleeding in cirrhosisISRCTN16334693Individual sponsor (Germany)186